Calidi Biotherapeutics Advancing RTNova in Collaboration with SIGA Technologies

June 10, 2024

DENVER, Colo., Jun 10, 2024 (247marketnews.com)- Calidi Biotherapeutics, Inc. (NYSE:CLDI) reported that it entered into a collaboration agreement with SIGA Technologies (Nasdaq:SIGA), in the first quarter of 2024, to support the development of Calidi’s RTNova (CLD-400) virotherapy platform.

“We believe RTNova is a major breakthrough, and Calidi’s novel systemic targeted virotherapy has the potential to radically shift the treatment landscape for patients across all tumor types,” commented Calidii’s CEO, Antonio F. Santidrian. “By partnering with SIGA, we will have access to a safety switch during the development process, which could provide assurance to patients, physicians, and regulatory bodies during future clinical trials. We are excited about the possibilities this collaboration brings.”

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (CLDI, SIGA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.